Search - tctmd.com

Displaying 81 - 100 of 122

Sort: Relevancy | Date

Presentation TCT 2015

Preprocedural Planning for the Watchman Device: Case Examples

Presenter: Maurice Buchbinder, Zoltan G. Turi, Shephal Doshi

October 13, 2015

Presentation TCT 2015

Watchman Generation 5 (Watchman Flex)

Presenter: Brij Maini, Horst Sievert

October 12, 2015

Presentation TCT 2015

Watchman Step-by-Step

Presenter: Maurice Buchbinder, Brian K. Whisenant, Mark Reisman

October 12, 2015

News Conference News TCT 2015

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

October 12, 2015

Presentation TCT 2015

Step-by-Step Review of LAA Procedures (Watchman and Lariat)

Presenter: Russell A. Brandwein, Steven J. Yakubov

October 11, 2015

Presentation TCT 2015

Comprehensive Analysis of the Watchman Data: PROTECT AF, CAP, and PREVAIL

Presenter: Reda Ibrahim, Matthew J. Price, David R. Holmes Jr.

October 11, 2015

News Conference News TCT 2015

Use of LAA Occlusion in Low-Risk Patients Debated

Todd Neale

October 11, 2015

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

Presentation TCT 2014

TCT 175: Preclinical Study of the Novel Generation of Watchman for Left Atrial Appendage Occlusion

Presenter: Josep Rodés-Cabau, Peter B Sick, Krzysztof Bartus, Dongming Hou

September 16, 2014

Presentation TCT 2014

Watchman Step-by-Step

Presenter: Saibal Kar, Horst Sievert, Jochen Wöhrle

September 16, 2014

Presentation TCT 2014

TCT 176: Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Shows a Significant Reduction in Risk

Presenter: John M. Lasala, Stuart J. Pocock, George Hanzel, MD

September 16, 2014

Presentation TCT 2014

Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Represents a Significant Reduction in Risk

Presenter: George Hanzel

September 16, 2014

Presentation TCT 2014

TCT 171: Avoidance of Major Bleeding with WATCHMAN Left Atrial Appendage Closure Compared with Long-term Oral Anticoagulation: A Pooled Analysis of Randomized Trials

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Matthew J. Price

September 15, 2014

Presentation TCT 2014

Yes, It Is a Good Option for Most Anticoagulation Eligible Patients

Presenter: Saibal Kar

September 15, 2014

Presentation TCT 2014

No, It Should Be Limited to Patients with Absolute Anticoagulation Contraindications

Presenter: Jai-Wun Park

September 15, 2014

Presentation TCT 2014

Watchman II: PROTECT-AF/PREVAIL Meta-analysis and Implications

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, David R. Holmes Jr.

September 15, 2014

Presentation TCT 2014

Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Vivek Y. Reddy

September 15, 2014

News Conference News TCT 2014

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

September 14, 2014

Presentation TCT 2014

Watchman Nightmare Case and Teaching Moment #2: Improper Device Sizing with Embolization

Presenter: Josep Rodés-Cabau, Carlos E. Ruiz, Vivek Y. Reddy

September 13, 2014

Presentation TCT 2014

Watchman Nightmare Case and Teaching Moment #1: A Perforation

Presenter: Josep Rodés-Cabau, Carlos E. Ruiz, Maurice Buchbinder

September 13, 2014

Advertisement

Preprocedural Planning for the Watchman Device: Case Examples

Watchman Generation 5 (Watchman Flex)

Watchman Step-by-Step

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

Step-by-Step Review of LAA Procedures (Watchman and Lariat)

Comprehensive Analysis of the Watchman Data: PROTECT AF, CAP, and PREVAIL

Use of LAA Occlusion in Low-Risk Patients Debated

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

TCT 175: Preclinical Study of the Novel Generation of Watchman for Left Atrial Appendage Occlusion

Watchman Step-by-Step

TCT 176: Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Shows a Significant Reduction in Risk

Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Represents a Significant Reduction in Risk

TCT 171: Avoidance of Major Bleeding with WATCHMAN Left Atrial Appendage Closure Compared with Long-term Oral Anticoagulation: A Pooled Analysis of Randomized Trials

Yes, It Is a Good Option for Most Anticoagulation Eligible Patients

No, It Should Be Limited to Patients with Absolute Anticoagulation Contraindications

Watchman II: PROTECT-AF/PREVAIL Meta-analysis and Implications

Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

Watchman Nightmare Case and Teaching Moment #2: Improper Device Sizing with Embolization

Watchman Nightmare Case and Teaching Moment #1: A Perforation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content